Ligand Pharmaceuticals Inc (NAS:LGND)
$ 122.55 -1.78 (-1.43%) Market Cap: 2.32 Bil Enterprise Value: 2.10 Bil PE Ratio: 48.82 PB Ratio: 2.73 GF Score: 75/100

Q4 2020 Ligand Pharmaceuticals Inc Earnings Call Transcript

Feb 03, 2021 / 01:30PM GMT
Release Date Price: $110.68 (+0.24%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Ligand Pharmaceuticals Q4 Earnings Conference Call. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Patrick O'Brien. Thank you. Please go ahead.

Patrick O;Brien
Ligand Pharmaceuticals Incorporated - SVP of IR

' -

Thank you, Brandy, and welcome to Ligand's Fourth Quarter 2020 Financial Results and Business Update Conference Call. All of our speakers for today's call are in separate locations. Speaking today for Ligand will be John Higgins, CEO; Matt Foehr, COO; and Matt Korenberg, CFO.

We will use non-GAAP financial measures, and some of our statements will be forward-looking. Additional information concerning risk factors and other matters concerning Ligand can be found in Ligand's earnings press release and our periodic filings with the SEC. Ligand undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this conference call.

I would now like to turn

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot